Treatment strategy of EGFR-mutated non-small cell lung cancer

被引：1
|
作者：
Tanaka, Fumihiro [1 ]
Yoneda, Kazue [1 ]
Takenaka, Masaru [1 ]
Kuroda, Koji [1 ]
机构：
[1] Univ Occupat & Environm Hlth, Dept Surg Chest Surg 2, 1-1 Iseigaoka, Kitakyushu, Fukuoka 8078555, Japan
来源：
JOURNAL OF THORACIC DISEASE | 2022年 / 14卷 / 03期
关键词：
OSIMERTINIB; PATIENT; MUTATIONS; SURGERY;
D O I：
10.21037/jtd-22-177
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
[No abstract available]
引用
收藏
页码：602 / 606
页数：5
相关论文
共 50 条
  • [31] Treatment in EGFR-mutated non-small cell lung cancer: how to block the receptor and overcome resistance mechanisms
    Proto, Claudia
    Lo Russo, Giuseppe
    Corrao, Giulia
    Ganzinelli, Monica
    Facchinetti, Francesco
    Minari, Roberta
    Tiseo, Marcello
    Garassino, Marina Chiara
    TUMORI JOURNAL, 2017, 103 (04): : 325 - 337
  • [32] Dacomitinib for the first-line treatment of patients with EGFR-mutated metastatic non-small cell lung cancer
    Santarpia, Mariacarmela
    Menis, Jessica
    Chaib, Imane
    Cao, Maria Gonzalez
    Rosell, Rafael
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2019, 12 (09) : 831 - 840
  • [33] Adjuvant treatment for EGFR-mutated non-small cell lung cancer: do we have a major breakthrough?
    Roviello, Giandomenico
    Imperatori, Marco
    Aieta, Michele
    Sollitto, Francesco
    Landriscina, Matteo
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S2114 - S2118
  • [34] Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer
    Chen, H.
    Lin, M.
    Jiang, J.
    Liu, M.
    Lai, Z.
    Luo, Y.
    Ye, H.
    Chen, H.
    Yang, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S55 - S55
  • [35] Pattern of Disease Progression on Osimertinib and Subsequent Treatment in Patients with EGFR-Mutated Non-Small Cell Lung Cancer
    Kim, H.
    Han, J.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1120 - S1120
  • [36] MERTK Activation Drives Osimertinib Resistance in EGFR-Mutated Non-Small Cell Lung Cancer
    Yan, D.
    Huelse, J.
    Parker, R.
    Wang, X.
    Frye, S.
    Earp, H. S.
    Deryckere, D.
    Graham, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1147 - S1147
  • [37] Tumor PKCδ instigates immune exclusion in EGFR-mutated non-small cell lung cancer
    Zuo, Yi-Han
    Gao, Wei-Na
    Xie, Ya-Jia
    Yang, Sheng-Yong
    Zhou, Jin-Tai
    Liang, Hai-Hai
    Fan, Xing-Xing
    BMC MEDICINE, 2022, 20 (01)
  • [38] Upfront osimertinib in EGFR-mutated non-small cell lung cancer: is brain still a sanctuary?
    Leonetti, Alessandro
    Facchinetti, Francesco
    Tiseo, Marcello
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6
  • [39] Stratifying Risk in Oligoprogressive EGFR-Mutated Non-Small Cell Lung Cancer: The Role of ctDNA
    Arrieta, O.
    Guijosa, A.
    Heredia, D.
    Davila-Dupont, D.
    Rios-Garcia, E.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S323 - S324
  • [40] Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism
    Hotta, Takamasa
    Tsubata, Yukari
    Hamai, Kosuke
    Tanino, Akari
    Kobayashi, Misato
    Nakamura, Atsushi
    Sugisaka, Jun
    Hongoh, Masafumi
    Ishihara, Noriyuki
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Fujitaka, Kazunori
    Kubota, Tetsuya
    Nishimura, Nobuhiro
    Isobe, Takeshi
    RESPIRATORY INVESTIGATION, 2021, 59 (03) : 327 - 334
12345